Cancer Cachexia Market Report 2025

This Cancer Cachexia market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The cancer cachexia market size has grown strongly in recent years. It will grow from $2.47 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.

The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives. Major trends in the forecast period include increasing research and development efforts, expanding therapeutic options, improved diagnosis rates, adoption of novel treatment modalities, and advancements in supportive care strategies.

The growing prevalence of cancer is expected to drive the expansion of the cancer cachexia market. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, leading to tumor formation and disruption of normal bodily functions. The increasing incidence of cancer is attributed to several factors, including lifestyle changes, environmental influences, aging populations, genetic predisposition, improved diagnostic techniques allowing for earlier detection, and greater public awareness, leading more individuals to seek medical attention. Advances in medical technology and a deeper understanding of cancer and its associated complications are contributing to more frequent diagnoses and reporting of cancer cachexia. Healthcare providers are becoming more adept at identifying the symptoms of cachexia, enabling earlier treatment interventions. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of the Australian population, or 456,200 individuals, were diagnosed with cancer in 2022. Additionally, the National Cancer Institute, a US-based federal agency, projected that 2,001,140 new cancer cases would be diagnosed in the U.S. in 2024, with 611,720 expected deaths. In 2022, there were nearly 20 million new cases and 9.7 million cancer-related deaths globally. By 2040, the number of new cancer cases is expected to reach 29.9 million annually, with cancer-related deaths rising to 15.3 million. Thus, the increasing prevalence of cancer is significantly driving the growth of the cancer cachexia market.

Key players in the cancer cachexia market are focusing on developing innovative treatments, such as monoclonal antibodies, to provide targeted solutions for managing cancer cachexia and improving patients' body weight, muscle mass, and overall quality of life. Monoclonal antibodies for cachexia work by targeting and inhibiting the factors responsible for muscle and weight loss. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical company, reported the positive results from its Phase 2 trial of Ponsegromab, a monoclonal antibody aimed at targeting GDF-15 in cancer cachexia patients. The study showed a significant increase in body weight, along with improvements in muscle mass, appetite, and physical activity, with the 400 mg dose yielding the most notable results. Following these encouraging outcomes, Pfizer plans to launch registration-enabling studies in 2025 to further explore Ponsegromab’s potential as a treatment for cancer cachexia.

In January 2023, LG Chem Ltd., a South Korean chemical company, acquired AVEO Oncology for an undisclosed amount. This acquisition aims to diversify LG Chem's product portfolio and enhance its capabilities in drug development, commercialization, and acquisitions, thereby accelerating its progress toward delivering cutting-edge cancer treatments. AVEO Oncology, a US-based biopharmaceutical company, provides a potential treatment for cancer cachexia.

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer cachexia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. This multifactorial condition arises from a combination of factors, including inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impair their ability to tolerate cancer treatments, and reduce overall survival.

The main therapeutics for cancer cachexia include progestogens, corticosteroids, combination therapies, and others. Progestogens, a type of medication often used in treating cancer cachexia, work by mimicking the effects of natural progesterone hormones in the body, potentially helping to increase appetite and muscle mass in patients. These treatments operate through various mechanisms, such as appetite stimulation and weight loss stabilization, and are distributed via hospital stores, retail pharmacies, and online pharmacies.

The cancer cachexia market research report is one of a series of new reports that provides cancer cachexia market statistics, including cancer cachexia industry global market size, regional shares, competitors with a cancer cachexia market share, detailed cancer cachexia market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cachexia industry. This cancer cachexia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer cachexia market consists of revenues earned by entities by providing services such as nutritional counseling, physical therapy, and exercise training. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cachexia market also includes sales of anabolic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral nutritional supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.